Overview

Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial

Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
An International Multi-Centre Randomised Adaptive Platform Clinical Trial to Assess the Clinical, Virological and Immunological Outcomes in Patients with SARS-CoV-2 Infection (COVID-19).
Phase:
Phase 3
Details
Lead Sponsor:
University of Melbourne
Collaborators:
Australasian Society for Infectious Diseases
Hunter Medical Research Institute
Middlemore Clinical Trials
The George Institute
The Peter Doherty Institute for Infection and Immunity
The University of Queensland
Treatments:
Dalteparin
Enoxaparin
Heparin, Low-Molecular-Weight
Hydroxychloroquine
Lopinavir
Nafamostat
Ritonavir
Tinzaparin